Midazolam Pharmacokinetics in Morbidly Obese Patients Following Semi-Simultaneous Oral and Intravenous Administration: A Comparison with Healthy Volunteers

BACKGROUND: While in vitro and animal studies have shown reduced cytochrome P450 (CYP) 3A activity due to obesity, clinical studies in (morbidly) obese patients are scarce. As CYP3A activity may influence both clearance and oral bioavailability in a distinct manner, in this study the pharmacokinetic...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Brill, Margreke J. E., van Rongen, Anne, Houwink, Aletta P. I., Burggraaf, Jacobus, van Ramshorst, Bert, Wiezer, René J., van Dongen, Eric P. A., Knibbe, Catherijne A. J.
Format: Artigo
Idioma:Inglês
Publicat: Springer International Publishing 2014
Matèries:
Original Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4171595/
https://ncbi.nlm.nih.gov/pubmed/25141974
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40262-014-0166-x
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars